Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
69
resultados
Última actualización
12/11/2026 [07:00:00]
Resultados 25 a 50 de 69
Resumen de: US20260272993A1
The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.
Resumen de: US20260265827A1
Methods of diagnosing inflammatory bowel disease (IBD), ulcerative colitis (UC) or Crohn's disease (CD) in a subject in need thereof, comprising receiving a stool sample from the subject and measuring DNA levels in the stool sample are provided. Kits comprising at least one reagent that detects mammalian DNA and not bacterial DNA and at least one reagent that detects cell type-specific DNA methylation are also provided.
Resumen de: AU2025228200A1
The present disclosure relates to dosage regimens for glucagon-like-peptide-2 (GLP-2) analogs, e.g., apraglutide, in a subject in need thereof, e.g., a subject with short bowel syndrome (SBS).
Resumen de: AU2026220293A1
Abstract The present invention relates to methods of immune modulation. In particular, the present invention relates to regulation of inflammation and immune responses by modulation of ABCF1. Modulation of ABCF1 may be useful in the treatment of sepsis, autoimmune diseases, cancer or infections. ug u g
Resumen de: US20260265828A1
Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.
Resumen de: US20260265841A1
In some embodiments, provided is a method for identifying a stool sample with an altered microbiome associated with IBD with disease above TI comprising the steps of: a) determining the relative abundance of a set of bacterial species in the stool sample; b) comparing the relative abundance of each bacterial species in the set of bacterial species from the individual with the relative abundance of each bacterial species in the set of bacterial species in a reference data set to generate a risk score; and c) determining the stool sample as having an altered microbiome associated with IBD with disease above the TI if the risk score is higher than a cutoff value. Other embodiments are described herein. In some embodiments, provided methods, kits, products and uses of compositions provide a cost-effective, non-invasive method to support clinical decision making, and hence to help improve disease management regarding disease above TI.
Resumen de: WO2026185407A1
The present invention is directed to compositions, including post-biotic compositions, comprising cereal gruel fermented by Lactobacillus plantarum 299 and/or Lactobacillus plantarum 299v®. The compositions are useful for 5 treating diseases in human beings, including liver diseases, as well as gastrointestinal diseases and inflammatory conditions related to liver diseases. Disease treatment and treatment efficacies may be monitored based on the development in selected patient groups of one or more biomarkers, including intestinal fatty acid-binding protein (I-FABP) and C-reactive protein 10 (CRP).
Resumen de: AU2025237849A1
Methods of identifying a canine subject susceptible to inflammatory bowel disease, methods of treating or preventing inflammatory bowel disease in a canine subject, and compositions useful for treating or preventing inflammatory bowel disease in a canine subject are described herein.
Resumen de: US2016060335A1
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Resumen de: US20260258116A1
0000 The present disclosure relates to anti-ToH1 antibodies, methods of generating anti-ToH1 antibodies, and methods of use of anti-ToH1 antibodies for diagnosis and treatment of microbial disease and/or chronic inflammatory disease, including microbial infection and microbe-associated chronic inflammatory conditions.
Resumen de: WO2020141608A1
The purpose of the present invention is to provide a test method and the like that is specific for ulcerative colitis and for primary sclerosing cholangitis. The present invention firstly provides a test method for ulcerative colitis, the test method being a detection step of detecting, in a sample and as an indicator of ulcerative colitis, an antibody that immunologically reacts with integrin αVβ6 and/or an antibody that immunologically reacts with integrin αVβ3. The present invention secondly provides a test method for primary sclerosing cholangitis, the test method being a detection step of detecting, in a sample and as an indicator of primary sclerosing cholangitis, an antibody that immunologically reacts with an antibody that immunologically reacts with integrin αVβ6 and/or integrin αVβ3.
Resumen de: WO2026178656A1
It is provided a biodegradable gel mimetic matrix for cells seeding, the mimetic matrix composed of a functionalized alginate and a functionalized biodegradable polymer with at least one peptide, such as PEG. The PEG carries vinyl-sulfone groups that enable it to interact with the peptides and alginate. Alginate controls the gelation and stiffness of the mimetic matrix. It is further provided a method of culturing cells onto the matrix, providing a model to study epithelial cell behaviour toward a pathological state like inflammatory bowel disease (IBD) or cancer, like colorectal cancer.
Resumen de: WO2026182113A1
A method for predicting endoscopic activity of ulcerative colitis, the method comprising: step (a) for measuring the concentration of one or more substances selected from the group consisting of C9, CYTF, LBP, Gelsolin, a1-Microglobulin, Resistin, MMP-8, MMP-9, HPT, C4, IGFBP-2, C3, and BIN2 in a blood sample of a subject; and step (b) for determining endoscopic activity of ulcerative colitis in the subject on the basis of the concentration of the protein in the blood sample measured in step (a).
Resumen de: MX2025013570A
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Resumen de: WO2025120137A1
The present invention relates to the field of mucins and mRNA isoforms thereof, more in particular the use of mucins and mRNA isoforms in subjects suspected having an intestinal disorder. Provided herein is an in vitro method for determining the presence of barrier damage to the intestinal tract and/or prediction of therapy response and recovery thereto by determining the expression of at least 3 mRNA isoforms originating from genes selected from the list comprising: MUC1, MUC2, MUC3A, MUC4, MUC5AC, MUC5B, MUC6, MUC12, MUC12-AS1, MUC13, MUC16, MUC17, MUC19, MUC20 or an overlapping transcript or a pseudogene thereof.
Resumen de: CN122643287A
The invention discloses an application of luteolin in preparation of a targeted ANGPTL4 medicine for treating colorectal cancer, particularly provides a comprehensive single cell resolution map for tumor microenvironment (TME) remodeling in the progress process of inflammatory bowel disease (IBD) related colorectal cancer (CRC), and discloses a multi-aspect anti-tumor effect of the luteolin. Including direct inhibition of tumors, normalizing TME, and inhibition of oncogenic secretory factor angiopoietin-like protein 4 (ANGPTL4). The ANGPTL4 is further identified as a luteolin response biomarker with functional significance in CRC pathogenesis, and a new way is opened up for risk stratification, treatment monitoring and potential targeted intervention.
Resumen de: CN122643332A
The invention relates to the technical field of IBS-D humanized models, and particularly discloses a construction method of a cold syndrome IBS-D humanized animal model, the model and application. The construction method comprises the following steps: screening IBS-D patients which meet Rome IV diagnostic standards and are dialectically cold in traditional Chinese medicine as coprophilous fungus donors, collecting fresh feces of the donors, and preparing coprophilous fungus suspension; transplanting the prepared coprophilous fungus suspension into the body of a sterile mouse through an intragastric administration way, and carrying out periodic field planting; after colonization is finished, the IBS-D disease phenotype and the traditional Chinese medicine cold syndrome phenotype of the receptor mouse are detected, and if the receptor mouse has the IBS-D disease phenotype and the traditional Chinese medicine cold syndrome phenotype at the same time, it is judged that the cold syndrome IBS-D humanized animal model is successfully constructed. According to the method, the flora-syndrome correlation model is created for the first time, the clinical simulation degree is high, a new mechanism research normal form is provided, a standardized modeling system is constructed, repeatability and stability are excellent, the drug evaluation dimension is expanded, and precise drug use is promoted.
Resumen de: CN122648564A
The invention belongs to the field of medical detection, and particularly relates to a detection kit for predicting response of ulcerative colitis patients to vializumab treatment, application of reagents in preparation of the kit and an integrated detection system.The kit comprises the reagents used for detecting expression levels of genes TMEM273, HSF1, SLC25A17 and STT3A in a subject sample; the expression levels of the four genes are used for predicting and evaluating whether the patient responds to vializumab. The invention has high specificity on alpha4beta7-targeted vializumab, and has no prediction efficiency on beta7-targeted etrazumab, thereby proving the non-pan inflammation index and high targeting accuracy of the etrazumab. According to the method, the crossing of liquid biopsy can be realized: the histological model shows obvious prediction efficiency in an independent peripheral blood queue, the technical bottleneck that the local immune genes of the intestinal tract cannot be detected through blood drawing is broken through, and the detection threshold and the pain of a patient are greatly reduced.
Resumen de: US20260250768A1
The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.
Resumen de: US20260250767A1
The present disclosure generally relates to the treatment of subjects having IBD or at risk of developing IBD by administering an Indoleamine 2,3-Dioxygenase 2 (IDO2) agonist or a SMAD Family Member 2 (SMAD2) agonist to the subject.
Resumen de: WO2025085674A1
In one aspect, the present disclosure provides a method for selecting a subject having ulcerative colitis for treatment with ADS051, or a pharmaceutically acceptable salt thereof, the method comprising: (a) measuring MRP2 seRNA in a stool sample obtained from the subject; and (b) selecting the subject for treatment when the level of MRP2 seRNA in the stool sample exceeds a threshold value. In some embodiments, the subject has moderate or severe ulcerative colitis.
Resumen de: WO2025085928A1
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Resumen de: CN122628157A
本发明涉及一种与皮质醇小分子特异性结合的人工从头设计蛋白，所述蛋白质的氨基酸序列如SEQ ID NO:1所示。本发明通过深度学习方法，针对皮质醇分子的空间结构、疏水特征以及官能团分布，使用模型构建与其匹配的结合口袋，使设计蛋白能够通过疏水相互作用、氢键作用及空间构象互补等方式与皮质醇形成稳定结合。相比天然蛋白随机筛选方式，本发明可通过结构约束提高结合位点与目标分子的匹配程度，从而提升对皮质醇的识别特异性。
Resumen de: CN122631891A
0001 本发明公开了一种用于区分结直肠癌与结直肠腺瘤的标志物及其应用，涉及生物医学技术领域，标志物选自以下任一项：由SELL、CD177、ITGAL、OLR1、B2M、LAG3组成的外泌体表面驱动标志物；由TGM3、PSMB4、KRT80、KRT2、DSG1、CPOX、CPN1、SUB1、LSM2、RAB34、PZP、SERPINA5、HYDIN、PGLYRP1组成的内部核心蛋白；KRT80单指标标志物。本发明能够实现结直肠癌与结直肠腺瘤的检测。
Nº publicación: CN122629194A 25/08/2026
Solicitante:
济南微生态生物医学省实验室
Resumen de: CN122629194A
0001 本发明公开了一种间充质基质细胞治疗克罗恩病的肠道微生物标志物、产品及其应用，本发明提供的肠道微生物标志物包括丹毒丝菌目、粪杆菌属、丹毒丝菌科、芽孢杆菌纲、乳杆菌目、乳杆菌科、紧密乳杆菌属、厚壁菌门、鼠杆菌科、拟杆菌目、拟杆菌纲、拟杆菌门、梭菌纲、毛螺菌目、毛螺菌科、梭菌纲UCG‑014、颤螺菌目中的一种或多种。通过检测上述标志物的含量或丰度，可预测间充质基质细胞治疗克罗恩病的疗效。本发明还提供了基于上述标志物构建疗效预测模型的方法，得到疗效预测模型。本发明能够实现对间充质基质细胞治疗克罗恩病疗效的提前预测，具有良好的临床应用前景。
BOPI
Sede Electrónica
